Company Description
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide.
Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.
The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic.
It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.
| Country | United States |
| Founded | 2010 |
| IPO Date | Feb 3, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10,600 |
| CEO | John V. Oyler |
Contact Details
Address: C/o Mourant Governance Services (Cayman), 94 Solaris Avenue, Camana Bay Grand Cayman, E9 KY1-1108 Cayman Islands | |
| Phone | 13459494123 |
| Website | beigene.com |
Stock Details
| Ticker Symbol | BGNE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001651308 |
| CUSIP Number | 07725L102 |
| ISIN Number | US07725L1026 |
| Employer ID | 98-1209416 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John V. Oyler | Co-Founder, Executive Chairman and Chief Executive Officer |
| Dr. Xiaobin Wu Ph.D. | President and Chief Operating Officer |
| Dr. Xiaodong Wang Ph.D. | Co- Chairman of Scientific Advisory Board and Non-Executive Director Co-Founder |
| Julia Wang | Chief Financial Officer and Principal Financial Officer |
| Wang Lai Ph.D. | Global Head of Research & Development |
| Titus B. Ball | Vice President and Chief Accounting Officer |
| Liza Heapes | Head of Investor Relations |
| Chan Lee | General Counsel and Senior Vice President |
| Yang Ji | Chief Compliance Officer |
| Dr. Yan Qi | Senior Vice President and Head of Public Affairs - Greater China |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 9, 2024 | 144 | Filing |
| Mar 26, 2024 | 144 | Filing |
| Mar 20, 2024 | 8-K | Current Report |
| Mar 15, 2024 | 8-K | Current Report |
| Mar 12, 2024 | 144 | Filing |
| Mar 8, 2024 | 8-K | Current Report |
| Feb 29, 2024 | 144 | Filing |
| Feb 26, 2024 | 10-K | Annual Report |
| Feb 26, 2024 | 8-K | Current Report |